Pfizer Inc ((PFE)), Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. and Bristol-Myers Squibb Company are conducting a Phase 1B study titled ‘A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA.’ The study aims to evaluate the safety and tolerability of combining elranatamab with iberdomide in patients with relapsed or refractory multiple myeloma, a cancer affecting plasma cells.
The study tests two drugs: elranatamab, a BCMA-CD3 bispecific antibody, and iberdomide, a cereblon-modulating agent. Elranatamab is administered as a subcutaneous injection, while iberdomide is taken orally.
This interventional study is randomized and follows a sequential intervention model without masking. Its primary purpose is treatment, focusing on determining the safe dosage levels of the drug combination.
The study began on February 20, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 28, 2025.
This clinical study could significantly impact Pfizer and Bristol-Myers Squibb’s market performance by potentially enhancing their oncology portfolios. Positive outcomes may boost investor confidence, especially in the competitive field of multiple myeloma treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.